1. Home
  2. SCYX vs BANL Comparison

SCYX vs BANL Comparison

Compare SCYX & BANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • BANL
  • Stock Information
  • Founded
  • SCYX 1999
  • BANL 2015
  • Country
  • SCYX United States
  • BANL Malaysia
  • Employees
  • SCYX N/A
  • BANL N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • BANL Oil Refining/Marketing
  • Sector
  • SCYX Health Care
  • BANL Energy
  • Exchange
  • SCYX Nasdaq
  • BANL Nasdaq
  • Market Cap
  • SCYX 28.5M
  • BANL 25.3M
  • IPO Year
  • SCYX 2014
  • BANL 2023
  • Fundamental
  • Price
  • SCYX $0.70
  • BANL $0.75
  • Analyst Decision
  • SCYX
  • BANL
  • Analyst Count
  • SCYX 0
  • BANL 0
  • Target Price
  • SCYX N/A
  • BANL N/A
  • AVG Volume (30 Days)
  • SCYX 138.2K
  • BANL 610.0K
  • Earning Date
  • SCYX 08-07-2025
  • BANL 04-16-2025
  • Dividend Yield
  • SCYX N/A
  • BANL N/A
  • EPS Growth
  • SCYX N/A
  • BANL N/A
  • EPS
  • SCYX N/A
  • BANL N/A
  • Revenue
  • SCYX $2,630,000.00
  • BANL $592,517,545.00
  • Revenue This Year
  • SCYX $463.61
  • BANL N/A
  • Revenue Next Year
  • SCYX $310.80
  • BANL N/A
  • P/E Ratio
  • SCYX N/A
  • BANL N/A
  • Revenue Growth
  • SCYX N/A
  • BANL 35.93
  • 52 Week Low
  • SCYX $0.66
  • BANL $0.55
  • 52 Week High
  • SCYX $2.29
  • BANL $1.35
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 38.69
  • BANL 41.80
  • Support Level
  • SCYX $0.67
  • BANL $0.72
  • Resistance Level
  • SCYX $0.75
  • BANL $1.03
  • Average True Range (ATR)
  • SCYX 0.04
  • BANL 0.08
  • MACD
  • SCYX 0.00
  • BANL -0.01
  • Stochastic Oscillator
  • SCYX 33.06
  • BANL 9.87

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About BANL CBL International Limited

CBL International Ltd is a marine fuel logistics company that provides a one-stop solution for vessel refueling. In the bunkering industry, it is referred to as a bunkering facilitator. It facilitates vessel refueling between ship operators and local physical distributors/traders by purchasing marine fuel, including fossil fuel and alternative fuel, from its suppliers and arranging for the suppliers to deliver the fuel to the customers. The company's customer base comprises container liners, bulk carriers, and tankers. Geographically, the company generates a majority of its revenue from China, followed by Hong Kong, Malaysia, Singapore, South Korea, and other regions.

Share on Social Networks: